Redeye updates its estimates and valuation following Lifco’s Q4 2023 report. We positively view the company preserving its margins in a challenging economic environment. Organic net sales growth of c-5% for the quarter represented a sequential deterioration that we failed to anticipate. While organic growth may remain in negative territory during coming quarters, our view of Lifco’s long-term investment case remains unchanged

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/